About: Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Na myším experimentálním modelu napodobujícím lidské karcinomy vyvolané HPV16 jsme zkoumali schopnost buněčných vakcín založených na dendritických bunkách inkubovaných s peptidy odvozenými z lidských onkoproteinů HPV16 E6/E7 vyvolat imunitní odpověď in vitro a vyvolat ochrannou imunitu. V imunizačních/expozičních experimentech jsme našli dobrou korelaci mezi účinností vakcín in vitro, určenou cytotoxickými testy s uvolňováním chrómu, a úrovní ochrany proti nádorovému růstu. Výsledky experimentů in vitro i in vito odhalily, že buněčné vakcíny založené na dendritických buňkách z kostní dřeně pulzovaných s peptidy, které přesahují délku optimální pro vazbu MHC 1. třídy a které obsahují epitop Th, jsou schopné proti MHC I pozitivním nádorům vyvolaným HPV16 vyvolat silnou a ochrannou imunitu založenou na CTL (cs)
  • We have investigated the capacity of cellular vaccines based on dendritic cells loaded with human HPV16 E6/E7 oncoprotein-derived peptides to induce immune responses in vitro and to elicit protective immunity in a murine experimental model mimicking human HPV16-associated carcinomas. We have found a good correlation between the vaccine efficacy in vitro, determined by chromium release cytotoxic tests, and the level of protection against tumour growth in immunization-challenge experiments. The results from both in vitro and in vivo experiments revealed that BMDC-based cellular vaccines pulsed with peptides, which exceed the length optimal for binding of the MHC class I and which harbour the Th epitope, are capable to elicit strong and protective CTL-based immunity against HPV16-associated MHC class I positive tumours
  • We have investigated the capacity of cellular vaccines based on dendritic cells loaded with human HPV16 E6/E7 oncoprotein-derived peptides to induce immune responses in vitro and to elicit protective immunity in a murine experimental model mimicking human HPV16-associated carcinomas. We have found a good correlation between the vaccine efficacy in vitro, determined by chromium release cytotoxic tests, and the level of protection against tumour growth in immunization-challenge experiments. The results from both in vitro and in vivo experiments revealed that BMDC-based cellular vaccines pulsed with peptides, which exceed the length optimal for binding of the MHC class I and which harbour the Th epitope, are capable to elicit strong and protective CTL-based immunity against HPV16-associated MHC class I positive tumours (en)
Title
  • Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects
  • Imunogenicita HPV16 E6/E7 peptidových vakcín odvozených z dendritických buněk: aktivace a obranný účinek CTL (cs)
  • Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects (en)
skos:prefLabel
  • Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects
  • Imunogenicita HPV16 E6/E7 peptidových vakcín odvozených z dendritických buněk: aktivace a obranný účinek CTL (cs)
  • Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects (en)
skos:notation
  • RIV/68378050:_____/04:00108994!RIV/2005/AV0/A23005/N
http://linked.open.../vavai/riv/strany
  • 184;193
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • P(GA301/01/0985), P(GA301/04/0492), P(KSK5011112), P(NC7148), P(NR7807), Z(AV0Z5052915)
http://linked.open...iv/cisloPeriodika
  • 6
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 567335
http://linked.open...ai/riv/idVysledku
  • RIV/68378050:_____/04:00108994
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • HPV16 E6/E7 peptides; dendritic cells; cytotoxic lymphocytes (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • CZ - Česká republika
http://linked.open...ontrolniKodProRIV
  • [6843343BAA77]
http://linked.open...i/riv/nazevZdroje
  • Folia Biologica
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 50
http://linked.open...iv/tvurceVysledku
  • Reiniš, Milan
  • Bieblová, Jana
  • Bubeník, Jan
  • Indrová, Marie
  • Velek, Jiří
  • Jandlová, Táňa
  • Vonka, V.
http://linked.open...n/vavai/riv/zamer
issn
  • 0015-5500
number of pages
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 77 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software